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BackgroundHepatitis Delta virus (HDV) Infection has a worldwide distribution, with
approximately 20 millions infected persons. Interferon (IFN) is the only approved
drug for the treatment of HDV infection which is still a difficult to treat disease.
Objectives To report a successful treatment of a patient with a chronic severe
hepatitis Delta using combination therapy with Pegylated interferon (PegIFN),
Tenofovir disoproxil fumarate (TDF) and Emtricitabine (FTC). Study Design The
patient, a 47 years -old male patient, originating from Dagestan (East Asia), suffered
of chronic hepatitis Delta infection. The patient was HBsAg, HBeAg, and anti-Delta
Ab (IgG) positive. Serum HBV-DNA level was elevated (more than 9 logUI/mL).
Serum HDV-RNA level was up to 5.6 log (copies/ml). Genotypes HBV/D and HDV-1
were demonstrated. The liver histology revealed chronic active hepatitis (Metavir
score: A2F2). The treatment was started with PegIFN (180 μg/week) for two months
and then TDF (300 mg/day) (combined later with FTC) was added. Results Sustained
response was obtained after 10 months of treatment and was accompanied by the
clearance of serum hepatitis B virus surface antigen with seroconversion to anti-
HBs. Conclusion This case report suggests that Delta infection may co-exist with
high replicative HBV infection and that combination therapy with PegIFN and
nucleoside/tide analogues seems to be more effective than IFN alone. Given that























Publié sur Okina (http://okina.univ-angers.fr)
